Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Ltd, an innovative biotech firm, has revealed an update on its iNKT cell therapy platform aimed at treating blood cancers and solid tumors, via a presentation for its upcoming non-deal investor roadshow. Their leading product, ALA-101, is a pioneering cell therapy targeting CD19 antigens on cancer cells and is being developed for allogeneic use. Additionally, Arovella is advancing its treatment scope for solid tumors with licensed technology and its proprietary IL-12-TM technology.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
